Vision
S*BIO targets defined molecular pathways to inhibit the development of select tumour types, positioning us as a leader in oncology drug discovery research.
S*BIO translates a profound understanding of cancer biology into best-in-class clinical compounds, establishing us as a preferred partner and collaborator in the development of innovative cancer treatments.
S*BIO transforms the lives of people with cancer by creating breakthrough therapies with improved clinical outcomes, demonstrating our determination to be a driving force in the fight against cancer.
Pipeline
| |
News
S*BIO Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis Patients
S*BIO Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies For Patients with Myelofibrosis (MF)
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
S*BIO Appoints Ms Tamar Howson as Interim Chief Executive Officer
Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
S*BIO Restructures Agreement with Onyx for JAK2 Inhibitor Program - S*BIO regains full rights to SB1518 and SB1578
S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
First Cancer Drug Developed in Singapore Shows Encouraging Results in Early Human Clinical Trials
S*BIO’s Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
S*BIO’s Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies
S*BIO’s Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma
| |
